Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PF-08046876

Antibody-drug conjugate · Cytotoxic, directed at integrin beta-6 (ITGB6) · developed by PFIZER

Phase 1 Most advanced trial
PFE Developer

What is PF-08046876?

PF-08046876 is an antibody-drug conjugate that binds integrin beta-6 (IB6) on tumor cells and carries a camptothecin analog, AMDCPT, linked by a cleavable glucuronide linker. After internalization and linker cleavage, the released payload inhibits DNA topoisomerase-1, causing cell cycle arrest and apoptosis. It is being studied in solid tumors including bladder, lung, head and neck, esophageal and pancreatic cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
integrin beta-6 (ITGB6), DNA topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at integrin beta-6 (ITGB6)
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
PFIZER (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Non-Small Cell Lung CancerAdvanced/Metastatic Solid TumorsBladder CancerCarcinoma, Non Small Cell LungCarcinoma, Squamous Cell of Head and NeckEsophageal AdenocarcinomaEsophageal CancerEsophageal Squamous Cell CarcinomaGastroesophageal Junction AdenocarcinomaHead and Neck CancerPancreatic AdenocarcinomaPancreatic CancerUrothelial Carcinoma

Other drugs acting on ITGB6

More from PFIZER

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind PF-08046876

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.